Cofrogliptin vs Vildagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Cofrogliptin
Marketed by Haisco Pharmaceutical Group
NCT04556851 · Phase 3 · completed
This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.
Next expected readout: June 2027 · NCT07122102 (registry estimate)
Reported efficacy
HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)
Result source: NCT04564872
Vildagliptin · Galvus
Marketed by Novartis and partners
NCT00099866 · Phase 3 · completed
The study was randomized and double-blind, with an active metformin comparator and 570 participants. Its primary endpoint was the surrogate measure of HbA1c change, and because no trial results are posted, it cannot be determined whether the primary comparison was favorable.
Reported efficacy
Change from baseline in HbA1c at 52 weeks: At the study end, significant HbA(1c) reductions from baseline were seen with both vildagliptin (-1.0 +/- 0.1%, P < 0.001) and metformin (-1.4 +/- 0.1%, P < 0.001) (missed)
Result source: NCT00099866
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cofrogliptin | Vildagliptin |
|---|---|---|
| HbA1c, change | -1.0% vs -1.1%avs linagliptin 5 mgNCT045648721 other result
| 7.2% vs 7.4%vs SU+MetforminNCT018715583 other results
|
| Body weight, change (kg) | —Not posted · NCT04556851 | -0.3 vs 1.4vs SU+MetforminNCT018715581 other result
|
| HbA1c below 7% | —Not posted · NCT04556851 | —Not posted · NCT00099866 |
| Fasting plasma glucose, change | —Not posted · NCT04556851 | -1.2 vs -0.0−1.2 vs placeboNCT02002221 |
| 3-point MACE (% with event) | —Not posted · NCT04556851 | —Not posted · NCT00099866 |
HbA1c, change
- Cofrogliptin
- -1.0% vs -1.1%avs linagliptin 5 mgNCT04564872
1 other result
- -1.0% vs -1.1% NCT04564872
- Vildagliptin
- 7.2% vs 7.4%vs SU+MetforminNCT01871558
3 other results
- -1.0% vs -0.1% NCT02002221
- -0.9% vs -0.6% NCT01882907
- 1.9% vs 2.3% NCT02007278
Body weight, change (kg)
- Cofrogliptin
- —Not posted · NCT04556851
- Vildagliptin
- -0.3 vs 1.4vs SU+MetforminNCT01871558
1 other result
- -0.1 vs 0.7 NCT01882907
HbA1c below 7%
- Cofrogliptin
- —Not posted · NCT04556851
- Vildagliptin
- —Not posted · NCT00099866
Fasting plasma glucose, change
- Cofrogliptin
- —Not posted · NCT04556851
- Vildagliptin
- -1.2 vs -0.0−1.2 vs placeboNCT02002221
3-point MACE (% with event)
- Cofrogliptin
- —Not posted · NCT04556851
- Vildagliptin
- —Not posted · NCT00099866
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Cofrogliptin: 1 of 5 rows · Vildagliptin: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cofrogliptin Rows use multiple source trials | Vildagliptin Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.59% @ 24wk25 mga,b,c,d NCT04556851 · Phase 3 · sponsor-reported, not registry data show 1 more dose-0.63% @ 24wkcofrogliptin (HSK7653) 10 mg NCT04556851 · Phase 3 · sponsor-reported, not registry data | -0.82% (n=39) @ 24wkb,c,d NCT01582243 · Phase 4 · registry result, not featured evidence · combination |
| Dropout rate | — | 10%e NCT02007278 · Phase 4 · registry result, not featured evidence · combination show 10 more results0% NCT01472432 · Phase 4 · registry result, not featured evidence 8.9%50mg once daily NCT01766778 · Phase 4 · registry result, not featured evidence 6.6%50mg twice daily NCT01766778 · Phase 4 · registry result, not featured evidence 7.5% NCT01582243 · Phase 4 · registry result, not featured evidence · combination 2.6% NCT02002221 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 12% NCT01882907 · Phase 4 · registry result, not featured evidence · add on 14.3% NCT01871558 · Phase 3 · registry result, not featured evidence · combination 0% NCT01822548 · Phase 3 · registry result, not featured evidence · combination —50 mg NCT01537120 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | — | —e NCT02007278 · Phase 4 · registry result, not featured evidence · combination show 10 more results— NCT01472432 · Phase 4 · registry result, not featured evidence 7.1%50mg once daily NCT01766778 · Phase 4 · registry result, not featured evidence 6.6%50mg twice daily NCT01766778 · Phase 4 · registry result, not featured evidence 2.5% NCT01582243 · Phase 4 · registry result, not featured evidence · combination 2.6% NCT02002221 · Phase 4 · registry result, not featured evidence — NCT01686932 · Phase 4 · registry result, not featured evidence 2.6% NCT01882907 · Phase 4 · registry result, not featured evidence · add on — NCT01871558 · Phase 3 · registry result, not featured evidence · combination — NCT01822548 · Phase 3 · registry result, not featured evidence · combination —50 mg NCT01537120 · Phase 1 · registry result, not featured evidence |
| Serious AEs | — | 0%e NCT02007278 · Phase 4 · registry result, not featured evidence · combination show 10 more results0% NCT01472432 · Phase 4 · registry result, not featured evidence 3.6%50mg once daily NCT01766778 · Phase 4 · registry result, not featured evidence 3.3%50mg twice daily NCT01766778 · Phase 4 · registry result, not featured evidence 2.5% NCT01582243 · Phase 4 · registry result, not featured evidence · combination 2.6% NCT02002221 · Phase 4 · registry result, not featured evidence 4% NCT01686932 · Phase 4 · registry result, not featured evidence 3.4% NCT01882907 · Phase 4 · registry result, not featured evidence · add on 0% NCT01871558 · Phase 3 · registry result, not featured evidence · combination 0% NCT01822548 · Phase 3 · registry result, not featured evidence · combination 0%50 mg NCT01537120 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | — | e influenza like illness 15% headache 10% arthralgia 5% NCT02007278 · Phase 4 · registry result, not featured evidence · combination show 9 more results50mg once daily upper respiratory tract infection 14.3% cough 3.6% dizziness 3.6% NCT01766778 · Phase 4 · registry result, not featured evidence 50mg twice daily cough 3.3% elevated liver function test 3.3% hyperkalemia 3.3% NCT01766778 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 12.5% constipation 7.5% vaginal infection 7.5% NCT01582243 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 12.8% (placebo 14.1%) hyperhidrosis 10.3% (placebo 2.6%) hunger 9% (placebo 3.8%) NCT02002221 · Phase 4 · registry result, not featured evidence hypoglycaemia 26% blood glucose decreased 8% NCT01686932 · Phase 4 · registry result, not featured evidence upper respiration infection 3.4% common cold 2.6% diarrhea 2.6% NCT01882907 · Phase 4 · registry result, not featured evidence · add on dyspepsia 4.8% renal colic 4.8% tooth abscess 4.8% NCT01871558 · Phase 3 · registry result, not featured evidence · combination hypoglycemia 0% NCT01822548 · Phase 3 · registry result, not featured evidence · combination 50 mg headache 17.4% (placebo 16.7%) upper respiratory tract infection 17.4% (placebo 16.7%) reaction site cannula 13% (placebo 20.8%) NCT01537120 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Vildagliptin
show 9 more results
show 1 more result
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · Vildagliptin's landscape